Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors

被引:0
|
作者
Angela M. Carter
Nilesh Kumar
Brendon Herring
Chunfeng Tan
Rachael Guenter
Rahul Telange
Wayne Howse
Fabrice Viol
Tyler R. McCaw
Hayden H. Bickerton
Priyanka Gupta
Frank Gillardon
Eugene A. Woltering
Deepti Dhall
John Totenhagen
Ronadip R. Banerjee
Elizabeth M. Kurian
Sushanth Reddy
Herbert Chen
Joerg Schrader
J. Bart Rose
M. Shahid Mukhtar
James A. Bibb
机构
[1] University of Alabama at Birmingham,Department of Surgery
[2] University of Alabama at Birmingham,Department of Biology
[3] University of Texas Southwestern Medical Center,Department of Psychiatry
[4] University Hospital Hamburg-Eppendorf,Department of Internal Medicine
[5] University of Alabama at Birmingham,Department of Medicine
[6] University of Alabama at Birmingham,UAB Comprehensive Diabetes Center
[7] CNS Diseases Research,Boehringer Ingelheim Pharma GmbH & Co. KG
[8] Louisiana State University Health Sciences Center,Department of Surgery
[9] University of Alabama at Birmingham,Department of Anatomic Pathology
[10] University of Alabama at Birmingham,Department of Radiology
[11] Johs Hopkins school of Medicine,Department of Medicine, Division of Endocrinology, Diabetees & Metabolism
[12] University of Texas Southwestern Medical Center,Department of Pathology
[13] University of Alabama at Birmingham,O’Neal Comprehensive Cancer Center
来源
Oncogenesis | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous population of neoplasms that arise from hormone-secreting islet cells of the pancreas and have increased markedly in incidence over the past four decades. Non-functional PanNETs, which occur more frequently than hormone-secreting tumors, are often not diagnosed until later stages of tumor development and have poorer prognoses. Development of successful therapeutics for PanNETs has been slow, partially due to a lack of diverse animal models for pre-clinical testing. Here, we report development of an inducible, conditional mouse model of PanNETs by using a bi-transgenic system for regulated expression of the aberrant activator of Cdk5, p25, specifically in β-islet cells. This model produces a heterogeneous population of PanNETs that includes a subgroup of well-differentiated, non-functional tumors. Production of these tumors demonstrates the causative potential of aberrantly active Cdk5 for generation of PanNETs. Further, we show that human PanNETs express Cdk5 pathway components, are dependent on Cdk5 for growth, and share genetic and transcriptional overlap with the INS-p25OE model. The utility of this model is enhanced by the ability to form tumor-derived allografts. This new model of PanNETs will facilitate molecular delineation of Cdk5-dependent PanNETs and the development of new targeted therapeutics.
引用
收藏
相关论文
共 50 条
  • [1] Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors
    Carter, Angela M.
    Kumar, Nilesh
    Herring, Brendon
    Tan, Chunfeng
    Guenter, Rachael
    Telange, Rahul
    Howse, Wayne
    Viol, Fabrice
    McCaw, Tyler R.
    Bickerton, Hayden H.
    Gupta, Priyanka
    Gillardon, Frank
    Woltering, Eugene A.
    Dhall, Deepti
    Totenhagen, John
    Banerjee, Ronadip R.
    Kurian, Elizabeth M.
    Reddy, Sushanth
    Chen, Herbert
    Schrader, Joerg
    Rose, J. Bart
    Mukhtar, M. Shahid
    Bibb, James A.
    ONCOGENESIS, 2021, 10 (12)
  • [2] Biomarkers of Cdk5 driven neuroendocrine tumors
    Carter, Angela M.
    Telange, Rahul
    Oltmann, Sarah
    Nwariaku, Fiemu
    Robinson, Bruce
    Grubbs, Elizabeth
    Bibb, James
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [3] Kinase Cdk5 in tumors
    Laurie A Dempsey
    Nature Immunology, 2016, 17 (9) : 1015 - 1015
  • [4] The Role of Cdk5 in Neuroendocrine Thyroid Cancer
    Pozo, Karine
    Castro-Rivera, Emely
    Tan, Chunfeng
    Plattner, Florian
    Schwach, Gert
    Siegl, Veronika
    Meyer, Douglas
    Guo, Ailan
    Gundara, Justin
    Mettlach, Gabriel
    Richer, Edmond
    Guevara, Jonathan A.
    Ning, Li
    Gupta, Anjali
    Hao, Guiyang
    Tsai, Li-Huei
    Sun, Xiankai
    Antich, Pietro
    Sidhu, Stanley
    Robinson, Bruce G.
    Chen, Herbert
    Nwariaku, Fiemu E.
    Pfragner, Roswitha
    Richardson, James A.
    Bibb, James A.
    CANCER CELL, 2013, 24 (04) : 499 - 511
  • [5] Understanding the Molecular Underpinnings of Neuronal Kinase CDK5 mediated Metabolic Vulnerabilities in Neuroendocrine Tumors
    Gupta, Priyanka
    Strange, Keehn
    Carter, Angela
    Telenge, Rahul
    Meijer, Laurent
    Ghayee, Hans
    Pacak, Karel
    Reddy, Sushanth
    Bibb, James
    FASEB JOURNAL, 2020, 34
  • [6] Cdk5
    Maccioni, RB
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (06): : 1517 - 1517
  • [7] Evaluation of Cdk5 inhibitors in neural crest tumors
    Norris, Robin E.
    Pink, John J.
    Pareek, Tej
    Letterio, John L.
    CANCER RESEARCH, 2016, 76
  • [8] Structural insights into Cdk5 activation by a neuronal Cdk5 activator
    Lim, HY
    Seow, KT
    Li, Q
    Kesuma, D
    Wang, JH
    Qi, RZ
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 285 (01) : 77 - 83
  • [9] Distinct functions of Cdk5(Y15) phosphorylation and Cdk5 activity in stress fiber formation and organization
    Qiao, Fengyu
    Gao, Chun Y.
    Tripathi, Brajendra K.
    Zelenka, Peggy S.
    EXPERIMENTAL CELL RESEARCH, 2008, 314 (19) : 3542 - 3550
  • [10] CDK5 inhibition suppresses pancreatic cancer tumorigenesis and metastasis
    Feldmann, Georg
    Strock, Christopher J.
    Mishra, Anjali
    Ball, Douglas W.
    Maitra, Anirban
    Nelkin, Barry D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3548S - 3548S